Learn about Omvoh's MOA and how it selectively binds to the p19 subunit of IL-23.

Omvoh delivered significant improvement in bowel urgency, reported by people with UC as one of the most disruptive symptoms. Lilly 's first approved treatment for a type of inflammatory bowel …

Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates …

Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis. [5] It is designed to attach to interleukin-23 (IL-23) and block its activity. [5]

Evidence from 2 clinical trials demonstrated that treatment with Omvoh improved symptoms and reduced severity of UC; this treatment effect with Omvoh was maintained for up to 52 weeks …

Jan 31, 2025 · The Food and Drug Administration (FDA) has approved Omvoh ® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults. Mirikizumab …

Nov 10, 2024 · Humanized immunoglobulin G4 (IgG 4) monoclonal antibody; interleukin-23 (IL-23) antagonist. Treatment of moderately to severely active ulcerative colitis in adults.

Omvoh is a prescription medication indicated for the treatment of adults with moderately to severely active ulcerative colitis.

THURSDAY, Jan. 16, 2025 -- The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults, …

Some people with ulcerative colitis or Crohn’s disease taking Omvoh experienced rapid symptom relief. Omvoh could help people achieve steroid-free remission at 1 year. * UC improvement …